• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB

MESOBLAST LIMITED - Announcements

0.00% ! $2.29
Market Cap $2.924B  !

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Announcements



MSB Trading haltPRICE SENSITIVE16/12/20 download Created with Sketch. 155.18KB
MSB Pause in TradingPRICE SENSITIVE16/12/20 download Created with Sketch. 116.28KB
MSB Mesoblast Phase 3 Chronic Heart Failure ResultsPRICE SENSITIVE15/12/20 download Created with Sketch. 130.08KB
MSB Mesoblast Corporate Update Webcast15/12/20 download Created with Sketch. 105.09KB
MSB Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD07/12/20 download Created with Sketch. 146.6KB
MSB Remestemcel-L FDA Fast Track Designation for COVID-19 ARDSPRICE SENSITIVE02/12/20 download Created with Sketch. 116.21KB
MSB Appendix 2A27/11/20 download Created with Sketch. 167.16KB
MSB Results of Meeting24/11/20 download Created with Sketch. 208.38KB
MSB CEO Presentation to 2020 Annual General Meeting24/11/20 download Created with Sketch. 1.7MB
MSB Mesoblast Chairman Message to 2020 AGM24/11/20 download Created with Sketch. 113.7KB
MSB Novartis and Mesoblast Remestemcel-L CollaborationPRICE SENSITIVE20/11/20 download Created with Sketch. 147.21KB
MSB First Quarter Results PresentationPRICE SENSITIVE20/11/20 download Created with Sketch. 2.18MB
MSB MSB Q1 Financial Results and Operational HighlightsPRICE SENSITIVE20/11/20 download Created with Sketch. 271.6KB
MSB First Quarter Financial Results on Form 6-KPRICE SENSITIVE20/11/20 download Created with Sketch. 590.73KB
MSB Mesoblast Corporate Update and Financial Results Webcast20/11/20 download Created with Sketch. 81.67KB
MSB DSMB Analysis Recommends to Continue P3 COVID-19 ARDS TrialPRICE SENSITIVE11/11/20 download Created with Sketch. 117.63KB
MSB COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4CPRICE SENSITIVE29/10/20 download Created with Sketch. 192.37KB
MSB Annual Report to shareholders26/10/20 download Created with Sketch. 3.05MB
MSB Notice of Annual General Meeting and Proxy Form26/10/20 download Created with Sketch. 357.21KB
MSB Appendix 4G and Corporate Governance Statement26/10/20 download Created with Sketch. 202.52KB
MSB Remestemcel Controlled Study in Crohns & Ulcerative Colitis22/10/20 download Created with Sketch. 126.07KB
MSB Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment13/10/20 download Created with Sketch. 115.52KB
MSB Update on BLA for Graft Versus Host DiseasePRICE SENSITIVE02/10/20 download Created with Sketch. 93.31KB
MSB Trading HaltPRICE SENSITIVE01/10/20 download Created with Sketch. 153.58KB
MSB MSB Wins Fierce Biotech Innovation Award for Remestemcel-LPRICE SENSITIVE15/09/20 download Created with Sketch. 109.05KB
MSB Appendix 2A10/09/20 download Created with Sketch. 167.69KB
MSB Change in substantial holding07/09/20 download Created with Sketch. 258.94KB
MSB DSMB Recommends Continuation of Phase 3 COVID-19 TrialPRICE SENSITIVE04/09/20 download Created with Sketch. 110.61KB
MSB Ethics Approval to Treat COVID-19 Patients in Australia02/09/20 download Created with Sketch. 112.63KB
MSB Change in substantial holding02/09/20 download Created with Sketch. 258.72KB
MSB MSB Annual Financial Results and Operational ProgressPRICE SENSITIVE27/08/20 download Created with Sketch. 270.6KB
MSB Annual Financial Results Presentation27/08/20 download Created with Sketch. 2.26MB
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE27/08/20 download Created with Sketch. 2.48MB
MSB Mesoblast 2020 Full Year Financial Results Webcast26/08/20 download Created with Sketch. 57.31KB
MSB Change in substantial holding24/08/20 download Created with Sketch. 271.29KB
MSB Change in substantial holding21/08/20 download Created with Sketch. 247.46KB
MSB Appendix 2A and Appendix 3G20/08/20 download Created with Sketch. 249.55KB
MSB ODAC Votes in Favor of Remestemcel-L for GvHDPRICE SENSITIVE14/08/20 download Created with Sketch. 117.69KB
MSB Trading HaltPRICE SENSITIVE13/08/20 download Created with Sketch. 155.11KB
MSB Change in substantial holding - Amendment12/08/20 download Created with Sketch. 284.13KB
MSB Change in substantial holding - Amendment12/08/20 download Created with Sketch. 265.5KB
MSB Update on Scheduled FDA Advisory Committee MeetingPRICE SENSITIVE11/08/20 download Created with Sketch. 109.23KB
MSB Change in substantial holding10/08/20 download Created with Sketch. 230.03KB
MSB Change in substantial holding07/08/20 download Created with Sketch. 85.81KB
MSB Appendix 2A06/08/20 download Created with Sketch. 163.17KB
MSB Proposed issue of Securities - MSB06/08/20 download Created with Sketch. 24.9KB
MSB COVID-19/GVHD Update, Quarterly Report and Appendix 4CPRICE SENSITIVE30/07/20 download Created with Sketch. 230.46KB
MSB Mesoblast Expands Executive Leadership Team24/07/20 download Created with Sketch. 131.59KB
MSB FDA Advisory Committee Sets Review Date for Remestemcel-LPRICE SENSITIVE21/07/20 download Created with Sketch. 108.87KB
MSB Appendix 3B, 2A with prospectus- Kentgrove Capital07/07/20 download Created with Sketch. 809.43KB
MSB EAP for Remestemcel-L in Children with MIS-C due to COVID-1906/07/20 download Created with Sketch. 108.82KB
MSB Appendix 2A30/06/20 download Created with Sketch. 163.22KB
MSB Appendix 3G with 3Ys24/06/20 download Created with Sketch. 267.14KB
MSB Appendix 2A16/06/20 download Created with Sketch. 166.58KB
MSB S&P DJI Announces June 2020 Quarterly RebalancePRICE SENSITIVE12/06/20 download Created with Sketch. 223.16KB
MSB Appendix 2A01/06/20 download Created with Sketch. 164.04KB
MSB Remestemcel-L Improves Outcomes in Inflammatory Lung DiseasePRICE SENSITIVE01/06/20 download Created with Sketch. 116.33KB
MSB MSB Reports Q3 Financial Results and Operational HighlightsPRICE SENSITIVE28/05/20 download Created with Sketch. 281.8KB
MSB Third Quarter Results Presentation28/05/20 download Created with Sketch. 1.72MB
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE28/05/20 download Created with Sketch. 614.49KB
MSB Change in substantial holding27/05/20 download Created with Sketch. 250.69KB
MSB 3 Articles on RYONCIL GvHD Trial Results Published in BBMT25/05/20 download Created with Sketch. 124.22KB
MSB Change in substantial holding19/05/20 download Created with Sketch. 159.15KB
MSB Cleansing Notice18/05/20 download Created with Sketch. 72.61KB
MSB Appendix 2As15/05/20 download Created with Sketch. 375.44KB
MSB Proposed issue of Securities - MSB13/05/20 download Created with Sketch. 27.78KB
MSB MSB Completes Financing For Covid-19 ARDS ManufacturingPRICE SENSITIVE13/05/20 download Created with Sketch. 144.68KB
MSB Trading HaltPRICE SENSITIVE11/05/20 download Created with Sketch. 170.3KB
MSB First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS06/05/20 download Created with Sketch. 128.22KB
MSB Phase 2/3 Trial in COVID-19 ARDS Begins EnrollmentPRICE SENSITIVE30/04/20 download Created with Sketch. 140.07KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE29/04/20 download Created with Sketch. 193.38KB
MSB 83% Survival in COVID-19 ARDS Patients with Remestemcel-LPRICE SENSITIVE24/04/20 download Created with Sketch. 144.87KB
MSB Inflammatory Lung Disease Outcomes For Presentation at ISCT17/04/20 download Created with Sketch. 116.14KB
MSB US NIH Trials Network to Conduct COVID-19 Phase 2/3 TrialPRICE SENSITIVE09/04/20 download Created with Sketch. 95.91KB
MSB FDA Clears IND for Remestemcel Use in COVID-19 ARDS PatientsPRICE SENSITIVE06/04/20 download Created with Sketch. 89.95KB
MSB FDA Accepts BLA for RYONCIL and Agrees to Priority ReviewPRICE SENSITIVE01/04/20 download Created with Sketch. 92.3KB
MSB Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting30/03/20 download Created with Sketch. 94.18KB
MSB Change of Director's Interest Notice20/03/20 download Created with Sketch. 71.77KB
MSB Appendix 2A17/03/20 download Created with Sketch. 147.18KB
MSB Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung DiseasePRICE SENSITIVE10/03/20 download Created with Sketch. 98.41KB
MSB Mesoblast Provides Half Year Results and Corporate UpdatePRICE SENSITIVE27/02/20 download Created with Sketch. 223.76KB
MSB Half Year Financial Results Presentation27/02/20 download Created with Sketch. 1.46MB
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE27/02/20 download Created with Sketch. 757.72KB
MSB Mesoblast Half Year FY 2020 Financial Results Analyst Call25/02/20 download Created with Sketch. 70.25KB
MSB Ryoncil Results in Children with Acute GvHD Presented at TCT24/02/20 download Created with Sketch. 146.94KB
MSB Appendix 3G21/02/20 download Created with Sketch. 131.61KB
MSB Positive Outcomes Using Remestemcel-L in Chronic GVHD20/02/20 download Created with Sketch. 94.61KB
MSB Appendix 2A07/02/20 download Created with Sketch. 165.97KB
MSB Mesoblast Submits Completed BLA for Ryoncil to US FDAPRICE SENSITIVE03/02/20 download Created with Sketch. 114.77KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE29/01/20 download Created with Sketch. 219.65KB
MSB Appendix 2A24/01/20 download Created with Sketch. 147.69KB
MSB Biotech Showcase Presentation15/01/20 download Created with Sketch. 2.05MB
MSB MSB Presents Commercial Plans at 2020 Biotech Showcase15/01/20 download Created with Sketch. 144.16KB
MSB Appendix 2A02/01/20 download Created with Sketch. 143.67KB
MSB MSB Files GvHD Clinical Efficacy and Safety Data with US FDAPRICE SENSITIVE02/01/20 download Created with Sketch. 128.07KB
MSB DMC Completes Final Review of Phase 3 Heart Failure TrialPRICE SENSITIVE18/12/19 download Created with Sketch. 119.18KB
MSB CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)PRICE SENSITIVE17/12/19 download Created with Sketch. 122.93KB
MSB CHF P3 Trial Accrues Sufficient Primary Endpoint EventsPRICE SENSITIVE17/12/19 download Created with Sketch. 122.57KB
MSB Ceasing to be a substantial holder05/12/19 download Created with Sketch. 212.21KB
MSB Change of Director's Interest Notice05/12/19 download Created with Sketch. 70.89KB
MSB Trading halt
16/12/20PRICE SENSITIVE download Created with Sketch. 155.18KB
MSB Pause in Trading
16/12/20PRICE SENSITIVE download Created with Sketch. 116.28KB
MSB Mesoblast Phase 3 Chronic Heart Failure Results
15/12/20PRICE SENSITIVE download Created with Sketch. 130.08KB
MSB Mesoblast Corporate Update Webcast
15/12/20 download Created with Sketch. 105.09KB
MSB Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
07/12/20 download Created with Sketch. 146.6KB
MSB Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
02/12/20PRICE SENSITIVE download Created with Sketch. 116.21KB
MSB Appendix 2A
27/11/20 download Created with Sketch. 167.16KB
MSB Results of Meeting
24/11/20 download Created with Sketch. 208.38KB
MSB CEO Presentation to 2020 Annual General Meeting
24/11/20 download Created with Sketch. 1.7MB
MSB Mesoblast Chairman Message to 2020 AGM
24/11/20 download Created with Sketch. 113.7KB
MSB Novartis and Mesoblast Remestemcel-L Collaboration
20/11/20PRICE SENSITIVE download Created with Sketch. 147.21KB
MSB First Quarter Results Presentation
20/11/20PRICE SENSITIVE download Created with Sketch. 2.18MB
MSB MSB Q1 Financial Results and Operational Highlights
20/11/20PRICE SENSITIVE download Created with Sketch. 271.6KB
MSB First Quarter Financial Results on Form 6-K
20/11/20PRICE SENSITIVE download Created with Sketch. 590.73KB
MSB Mesoblast Corporate Update and Financial Results Webcast
20/11/20 download Created with Sketch. 81.67KB
MSB DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
11/11/20PRICE SENSITIVE download Created with Sketch. 117.63KB
MSB COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
29/10/20PRICE SENSITIVE download Created with Sketch. 192.37KB
MSB Annual Report to shareholders
26/10/20 download Created with Sketch. 3.05MB
MSB Notice of Annual General Meeting and Proxy Form
26/10/20 download Created with Sketch. 357.21KB
MSB Appendix 4G and Corporate Governance Statement
26/10/20 download Created with Sketch. 202.52KB
MSB Remestemcel Controlled Study in Crohns & Ulcerative Colitis
22/10/20 download Created with Sketch. 126.07KB
MSB Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
13/10/20 download Created with Sketch. 115.52KB
MSB Update on BLA for Graft Versus Host Disease
02/10/20PRICE SENSITIVE download Created with Sketch. 93.31KB
MSB Trading Halt
01/10/20PRICE SENSITIVE download Created with Sketch. 153.58KB
MSB MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
15/09/20PRICE SENSITIVE download Created with Sketch. 109.05KB
MSB Appendix 2A
10/09/20 download Created with Sketch. 167.69KB
MSB Change in substantial holding
07/09/20 download Created with Sketch. 258.94KB
MSB DSMB Recommends Continuation of Phase 3 COVID-19 Trial
04/09/20PRICE SENSITIVE download Created with Sketch. 110.61KB
MSB Ethics Approval to Treat COVID-19 Patients in Australia
02/09/20 download Created with Sketch. 112.63KB
MSB Change in substantial holding
02/09/20 download Created with Sketch. 258.72KB
MSB MSB Annual Financial Results and Operational Progress
27/08/20PRICE SENSITIVE download Created with Sketch. 270.6KB
MSB Annual Financial Results Presentation
27/08/20 download Created with Sketch. 2.26MB
MSB Preliminary Final Report including Appendix 4E
27/08/20PRICE SENSITIVE download Created with Sketch. 2.48MB
MSB Mesoblast 2020 Full Year Financial Results Webcast
26/08/20 download Created with Sketch. 57.31KB
MSB Change in substantial holding
24/08/20 download Created with Sketch. 271.29KB
MSB Change in substantial holding
21/08/20 download Created with Sketch. 247.46KB
MSB Appendix 2A and Appendix 3G
20/08/20 download Created with Sketch. 249.55KB
MSB ODAC Votes in Favor of Remestemcel-L for GvHD
14/08/20PRICE SENSITIVE download Created with Sketch. 117.69KB
MSB Trading Halt
13/08/20PRICE SENSITIVE download Created with Sketch. 155.11KB
MSB Change in substantial holding - Amendment
12/08/20 download Created with Sketch. 284.13KB
MSB Change in substantial holding - Amendment
12/08/20 download Created with Sketch. 265.5KB
MSB Update on Scheduled FDA Advisory Committee Meeting
11/08/20PRICE SENSITIVE download Created with Sketch. 109.23KB
MSB Change in substantial holding
10/08/20 download Created with Sketch. 230.03KB
MSB Change in substantial holding
07/08/20 download Created with Sketch. 85.81KB
MSB Appendix 2A
06/08/20 download Created with Sketch. 163.17KB
MSB Proposed issue of Securities - MSB
06/08/20 download Created with Sketch. 24.9KB
MSB COVID-19/GVHD Update, Quarterly Report and Appendix 4C
30/07/20PRICE SENSITIVE download Created with Sketch. 230.46KB
MSB Mesoblast Expands Executive Leadership Team
24/07/20 download Created with Sketch. 131.59KB
MSB FDA Advisory Committee Sets Review Date for Remestemcel-L
21/07/20PRICE SENSITIVE download Created with Sketch. 108.87KB
MSB Appendix 3B, 2A with prospectus- Kentgrove Capital
07/07/20 download Created with Sketch. 809.43KB
MSB EAP for Remestemcel-L in Children with MIS-C due to COVID-19
06/07/20 download Created with Sketch. 108.82KB
MSB Appendix 2A
30/06/20 download Created with Sketch. 163.22KB
MSB Appendix 3G with 3Ys
24/06/20 download Created with Sketch. 267.14KB
MSB Appendix 2A
16/06/20 download Created with Sketch. 166.58KB
MSB S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20PRICE SENSITIVE download Created with Sketch. 223.16KB
MSB Appendix 2A
01/06/20 download Created with Sketch. 164.04KB
MSB Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
01/06/20PRICE SENSITIVE download Created with Sketch. 116.33KB
MSB MSB Reports Q3 Financial Results and Operational Highlights
28/05/20PRICE SENSITIVE download Created with Sketch. 281.8KB
MSB Third Quarter Results Presentation
28/05/20 download Created with Sketch. 1.72MB
MSB Third Quarter Financial Results on Form 6-K
28/05/20PRICE SENSITIVE download Created with Sketch. 614.49KB
MSB Change in substantial holding
27/05/20 download Created with Sketch. 250.69KB
MSB 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
25/05/20 download Created with Sketch. 124.22KB
MSB Change in substantial holding
19/05/20 download Created with Sketch. 159.15KB
MSB Cleansing Notice
18/05/20 download Created with Sketch. 72.61KB
MSB Appendix 2As
15/05/20 download Created with Sketch. 375.44KB
MSB Proposed issue of Securities - MSB
13/05/20 download Created with Sketch. 27.78KB
MSB MSB Completes Financing For Covid-19 ARDS Manufacturing
13/05/20PRICE SENSITIVE download Created with Sketch. 144.68KB
MSB Trading Halt
11/05/20PRICE SENSITIVE download Created with Sketch. 170.3KB
MSB First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS
06/05/20 download Created with Sketch. 128.22KB
MSB Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
30/04/20PRICE SENSITIVE download Created with Sketch. 140.07KB
MSB Appendix 4C - quarterly
29/04/20PRICE SENSITIVE download Created with Sketch. 193.38KB
MSB 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
24/04/20PRICE SENSITIVE download Created with Sketch. 144.87KB
MSB Inflammatory Lung Disease Outcomes For Presentation at ISCT
17/04/20 download Created with Sketch. 116.14KB
MSB US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
09/04/20PRICE SENSITIVE download Created with Sketch. 95.91KB
MSB FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
06/04/20PRICE SENSITIVE download Created with Sketch. 89.95KB
MSB FDA Accepts BLA for RYONCIL and Agrees to Priority Review
01/04/20PRICE SENSITIVE download Created with Sketch. 92.3KB
MSB Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
30/03/20 download Created with Sketch. 94.18KB
MSB Change of Director's Interest Notice
20/03/20 download Created with Sketch. 71.77KB
MSB Appendix 2A
17/03/20 download Created with Sketch. 147.18KB
MSB Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
10/03/20PRICE SENSITIVE download Created with Sketch. 98.41KB
MSB Mesoblast Provides Half Year Results and Corporate Update
27/02/20PRICE SENSITIVE download Created with Sketch. 223.76KB
MSB Half Year Financial Results Presentation
27/02/20 download Created with Sketch. 1.46MB
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/20PRICE SENSITIVE download Created with Sketch. 757.72KB
MSB Mesoblast Half Year FY 2020 Financial Results Analyst Call
25/02/20 download Created with Sketch. 70.25KB
MSB Ryoncil Results in Children with Acute GvHD Presented at TCT
24/02/20 download Created with Sketch. 146.94KB
MSB Appendix 3G
21/02/20 download Created with Sketch. 131.61KB
MSB Positive Outcomes Using Remestemcel-L in Chronic GVHD
20/02/20 download Created with Sketch. 94.61KB
MSB Appendix 2A
07/02/20 download Created with Sketch. 165.97KB
MSB Mesoblast Submits Completed BLA for Ryoncil to US FDA
03/02/20PRICE SENSITIVE download Created with Sketch. 114.77KB
MSB Appendix 4C - quarterly
29/01/20PRICE SENSITIVE download Created with Sketch. 219.65KB
MSB Appendix 2A
24/01/20 download Created with Sketch. 147.69KB
MSB Biotech Showcase Presentation
15/01/20 download Created with Sketch. 2.05MB
MSB MSB Presents Commercial Plans at 2020 Biotech Showcase
15/01/20 download Created with Sketch. 144.16KB
MSB Appendix 2A
02/01/20 download Created with Sketch. 143.67KB
MSB MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
02/01/20PRICE SENSITIVE download Created with Sketch. 128.07KB
MSB DMC Completes Final Review of Phase 3 Heart Failure Trial
18/12/19PRICE SENSITIVE download Created with Sketch. 119.18KB
MSB CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
17/12/19PRICE SENSITIVE download Created with Sketch. 122.93KB
MSB CHF P3 Trial Accrues Sufficient Primary Endpoint Events
17/12/19PRICE SENSITIVE download Created with Sketch. 122.57KB
MSB Ceasing to be a substantial holder
05/12/19 download Created with Sketch. 212.21KB
MSB Change of Director's Interest Notice
05/12/19 download Created with Sketch. 70.89KB
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$2.29
Change
0.000(0.00%)
Mkt cap ! $2.924B
Open High Low Value Volume
$2.26 $2.31 $2.25 $1.912M 837.8K

Buyers (Bids)

No. Vol. Price($)
54 50684 $2.29
 

Sellers (Offers)

Price($) Vol. No.
$2.30 66643 34
View Market Depth
Last trade - 12.34pm 12/08/2025 (20 minute delay) ?
Last
$2.30
  Change
0.000 ( 1.21 %)
Open High Low Volume
$2.27 $2.31 $2.26 306716
Last updated 12.54pm 12/08/2025 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.